EP
TEVA icon

Eversept Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Eversept Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-660,177
Closed -$20.6M – 147
2025
Q4 		$20.6M Sell
660,177
-703,476
-52% -$17.3M 1.04% 26
2025
Q3 		$27.5M Buy
1,363,653
+310,772
+30% +$5.46M 1.9% 18
2025
Q2 		$17.6M Sell
1,052,881
-357,884
-25% -$5.78M 1.62% 21
2025
Q1 		$21.7M Sell
1,410,765
-831,360
-37% -$14.9M 2.2% 14
2024
Q4 		$49.4M Sell
2,242,125
-992,513
-31% -$18.1M 4.39% 7
2024
Q3 		$58.3M Sell
3,234,638
-1,485,822
-31% -$26M 3.99% 9
2024
Q2 		$76.7M Sell
4,720,460
-1,304,709
-22% -$20.1M 5.25% 5
2024
Q1 		$85M Sell
6,025,169
-129,185
-2% -$1.63M 5.67% 5
2023
Q4 		$64.3M Sell
6,154,354
-797,731
-11% -$7.45M 5.64% 5
2023
Q3 		$70.9M Sell
6,952,085
-715,959
-9% -$6.67M 6% 5
2023
Q2 		$57.7M Buy
7,668,044
+1,473,472
+24% +$11.9M 4.83% 5
2023
Q1 		$54.8M Buy
6,194,572
+1,481,975
+31% +$14.7M 3.82% 6
2022
Q4 		$43M Buy
4,712,597
+649,662
+16% +$5.67M 3.76% 8
2022
Q3 		$32.8M Sell
4,062,935
-447,767
-10% -$3.96M 2.84% 10
2022
Q2 		$33.9M Buy
4,510,702
+367,100
+9% +$3.2M 2.41% 12
2022
Q1 		$38.9M Buy
4,143,602
+1,842,104
+80% +$15.4M 2.99% 11
2021
Q4 		$18.4M Sell
2,301,498
-1,253,306
-35% -$11.3M 1.18% 25
2021
Q3 		$34.6M Sell
3,554,804
-249,601
-7% -$2.34M 2.39% 15
2021
Q2 		$37.7M Sell
3,804,405
-550,351
-13% -$5.83M 2.51% 13
2021
Q1 		$50.3M Buy
4,354,756
+1,606,506
+58% +$18.4M 3.78% 6
2020
Q4 		$26.5M Buy
2,748,250
+353,895
+15% +$3.39M 3.11% 13
2020
Q3 		$21.6M Buy
+2,394,355
New +$25.3M 4.79% 6

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eversept Partners's TEVA Position: Q1 2026 in Review

Eversept Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 660,177 shares — an estimated $20.6M sold.

Eversept Partners first reported a position in TEVA in Q3 2020 and held it in 22 quarters. The position peaked at $85M in Q1 2024. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Eversept Partners reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Eversept Partners sold 660,177 Teva Pharmaceuticals shares in Q1 2026, an estimated $20.6M.
  • Eversept Partners first reported a position in Teva Pharmaceuticals in Q3 2020 and held it in 22 quarters.
  • Eversept Partners's Teva Pharmaceuticals position peaked at $85M in Q1 2024.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.